Lastly, given the significance of the PD-1/PD-L1 pathway as a crucial target in cancer immunotherapy, chemotherapeutic molecules with the ability to downregulate PD-L1 expression in tumor cells hold promise for enhancing the immune response. Here, CD274 is linked to cancer.